Ironwood Pharmaceuticals (IRWD) EBITDA (2010 - 2026)

Ironwood Pharmaceuticals has disclosed EBITDA across 17 years of filings, most recently posting $79.3 million for Q2 2026.

• In Q2 2026, EBITDA rose 74.99% year-over-year to $79.3 million; the TTM figure through Jun 2026 stood at $234.2 million (up 219.29% YoY), while the FY2025 annual figure was $98.5 million, up 5.78% from the prior year.
• EBITDA came in at $79.3 million for Q2 2026 at Ironwood Pharmaceuticals, up from $72.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $79.3 million in Q2 2026 to a low of -$1.1 billion in Q2 2023.
• Average EBITDA over 5 years is -$19.5 million, with a median of $42.7 million recorded in 2023.
• Year-over-year, EBITDA slumped 2046.17% in 2023 and jumped 349.32% in 2026.
• Over 5 years, EBITDA stood at $68.4 million in 2022, then plunged by 45.02% to $37.6 million in 2023, then decreased by 16.22% to $31.5 million in 2024, then sank by 78.39% to $6.8 million in 2025, then surged by 1065.42% to $79.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $79.3 million in Q2 2026, $72.6 million in Q1 2026, and $6.8 million in Q4 2025.